| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of Psychiatry, Neurology, and Diagnostic Radiology, Yale University School of Medicine, New Haven, Connecticut
Correspondence: For correspondence or reprints contact: Christopher H. van Dyck, MD, CB 2041, Yale University School of Medicine, 333 Cedar St. New Haven, CT 06520.
ABSTRACT
SPECT has shown increasing promise as a diagnostic tool in Alzheimer's disease (AD). Recently, a new SPECT brain perfusion agent, 99mTc-ethyl cysteinate dimer (99mTc-ECD) has emerged with purported advantages in image quality over the established tracer, 99mTc-hexamethylpropyleneamine oxime (99mTc-HMPAO). This research aimed to compare cerebral images for 99mTc-HMPAO and 99mTc-ECD in discriminating patients with AD from control subjects. Methods: Twenty-four AD patients (mean age ± s.d. = 68.9 ± 8.2 yr) and 13 healthy subjects (68.4 ±_ 8.0 yr) were scanned sequentially with 20 mCi of each tracer using the CERASPECT system within 1 mo. Scanning began on average 11.5 ± 2.8 min after 99mTc-HMPAO injection and 41.8 ± 10.1 min after 99mTc-ECD. A ratio, R, was derived of count densities in "typically affected" brain structures (parietal and temporal association cortices) to "unaffected" structures (cerebellum, basal ganglia, thalamus, occipital cortex, and sensorimotor cortex). Results: Analysis of variance revealed significant interaction between diagnostic group and radiopharmaceutical (F = 4.71; df = 1,35; p = 0.04), with 99mTc-ECD demonstrating better separation of R values between AD patients and control subjects than 99mTc-HMPAO. Receiver operating characteristic (ROC) analysis revealed no significant difference in the ability of the two tracers to correctly classify AD patients and control subjects. Both tracers showed high diagnostic accuracy (99mTc-ECD: sensitivity = 100%, specificity = 92%; 99mTc-HMPAO: sensitivity = 100%, specificity = 85%). Conclusion: Technetium-99m-ECD shows greater contrast than 99mTc-HMPAO between affected and unaffected brain structures in AD when patients are compared to age-matched control subjects. Both tracers perform equally well in correctly classifying patients and control subjects.
Key Words: SPECT • Alzheimer's disease • technetium-99m-HMPAO • technetium-99m-ECD
This article has been cited by other articles:
|
|
 |
|
  A. A. Mroczenski, S. M. Berent, A. A. Hall, J. C. Hung, T. J. Herold, and B. P. Mullan Trends of Radiopharmaceutical Use at Mayo Clinic Rochester J. Nucl. Med. Technol., September 1, 2007; 35(3): 154 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Dougall, S. Bruggink, and K. P. Ebmeier Systematic Review of the Diagnostic Accuracy of 99mTc-HMPAO-SPECT in Dementia Am J Geriatr Psychiatry, December 1, 2004; 12(6): 554 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Norfray and J. M. Provenzale Alzheimer's Disease: Neuropathologic Findings and Recent Advances in Imaging Am. J. Roentgenol., January 1, 2004; 182(1): 3 - 13. [Full Text] [PDF]
|
|
|
|
 |
|
 C P Chang, Y C Shiau, J J Wang, S T Ho, and A Kao Abnormal regional cerebral blood flow on 99mTc ECD brain SPECT in patients with primary Sjogren's syndrome and normal findings on brain magnetic resonance imaging Ann Rheum Dis, September 1, 2002; 61(9): 774 - 778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. van Dyck, J. Gelernter, M. G. MacAvoy, R. A. Avery, M. Criden, O. Okereke, P. Varma, J. P. Seibyl, and P. B. Hoffer Absence of an Apolipoprotein E {epsilon}4 Allele Is Associated With Increased Parietal Regional Cerebral Blood Flow Asymmetry in Alzheimer Disease Arch Neurol, November 1, 1998; 55(11): 1460 - 1466. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
